drugset / Trial / NCT01292252

Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion

NCT01292252

Phase 4 Completed 36 enrolled Shane Burch Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effects of 12 weeks of daily treatment with teriparatide on spine fusion in adult patients who are undergoing multi-level posterolateral spine fusion surgery for degenerative conditions of the lumbar spine.

Timeline

Start
2011-08
Primary completion
2015-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous